Physician profile
Christopher Cornell Glaser
NPI 1053311621
$2,264.52
in general payments reported to CMS, 2019-2025
31 companies · $93.02 in 2025
The $93.02 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $241 · 2021: $337 · 2022: $363 · 2023: $249 · 2024: $468 · 2025: $93.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746 · Education: $63.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.44 |
| Education | $63.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $287.40 | 2021-2024 | Sonicision, Eea, Situate |
| Ethicon US, LLC | $209.38 | 2019-2024 | Enseal X1 |
| Solventum Corporation | $183.73 | 2024 | Prevena, V.A.C.Instill, Activ.A.C. |
| Davol INC. | $169.27 | 2020-2023 | Phasix Mesh |
| Covidien LP | $168.19 | 2019-2020 | |
| Tela Bio, INC. | $137.96 | 2019-2021 | |
| Boston Scientific Corporation | $134.92 | 2020-2023 | Eluvia |
| Janssen Pharmaceuticals, INC | $123.19 | 2021-2022 | |
| Daiichi Sankyo INC. | $106.06 | 2019-2025 | Datroway |
| Csl Behring | $94.02 | 2023-2024 | Kcentra |
| Innocoll Pharmaceuticals Limited | $87.22 | 2022 | |
| Lemaitre Vascular, INC. | $56.06 | 2019 | |
| Merck Sharp & Dohme LLC | $49.93 | 2021-2023 | Keytruda, Lynparza |
| Pacira Pharmaceuticals Incorporated | $48.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $40.47 | 2022 | |
| Melinta Therapeutics, LLC | $39.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.97 | 2020-2023 | Gattex |
| Abbvie INC. | $31.52 | 2022 | |
| Bard Peripheral Vascular, INC. | $28.96 | 2021-2023 | Rotarexs 6 F X 135 Cm |
| Braintree Laboratories, INC. | $28.85 | 2019-2022 | |
| Heron Therapeutics, INC. | $19.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.36 | 2022 | |
| Medline Industries LP | $19.21 | 2019 | |
| Ekos Corporation | $17.77 | 2019 | |
| Merit Medical Systems INC | $15.79 | 2023 | Savi Scout |
| Olympus America INC. | $15.74 | 2023 | 4k Cable 8.5m |
| Hologic INC | $14.45 | 2021 | |
| W. L. Gore & Associates, INC. | $13.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.96 | 2022 | |
| Polynovo North America LLC | $9.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Glaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.